OS Therapies (OSTX) Cash from Financing Activities (2023 - 2026)

OS Therapies (OSTX) has 4 years of Cash from Financing Activities data on file, last reported at $5.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 394.9% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (up 3.6% YoY) and the FY2025 annual result came in at $9.4 million, down 26.11% from the prior year.
• Cash from Financing Activities advanced to $5.2 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $6.0 million in Q4 2024 to a low of $525079.0 in Q2 2023.
• A 4-year average of $2.3 million and a median of $1.1 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 576.69% — and 2025, when it plunged 64.9%.
• Tracing OSTX's Cash from Financing Activities over 4 years: stood at $894064.0 in 2023, then jumped by 576.69% to $6.0 million in 2024, then sank by 64.9% to $2.1 million in 2025, then surged by 145.41% to $5.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $5.2 million (Q1 2026), $2.1 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.